OLMA:NASDAQ, Olema Pharmaceuticals, Inc.

OLMA stock overview

Olema Pharmaceuticals, Inc. (OLMA:NASDAQ) closed at $6.41 on October 23, 2026, down 8.69% on the day. The stock trades 82.3% below its 52-week high of $36.26 and 2.8% above its 52-week low of $6.24. Over the past year, it lost 20.2%. Olema Pharmaceuticals, Inc. is part of the Health Care sector.

Key figures

Price: $6.41
Day change: -8.69%
Volume: 1,984,562
Average volume: 1,120,220
Market cap: 560M+
52-week range: $6.24 – $36.26
50-day average: $9.30
200-day average: $14.65

Price action over the past year

In 252 trading sessions since October 23, 2025, OLMA closed higher on 112 days (44%). Its best day was November 18, 2025 (+136.38%) and its worst was March 9, 2026 (-25.75%). The stock moved 10% or more in a single session 8 times. It opened at least 5% above the previous day's high 2 times.

Recent signals

Oct 23, 2026: Down 29.1% over 30 days, from $9.04 (Dips & Crashes scanner)
Oct 23, 2026: Trading sideways between $6.41 and $7.36 over 14 days (Sideways scanner)
Oct 23, 2026: Hit a new 52-Week Low of $6.41 (New Highs/Lows scanner)
Oct 19, 2026: News catalyst: Biotech (News Catalysts scanner)

OLMA news

Oct 19, 2026: The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema Oncology
Oct 16, 2026: 4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month
Oct 5, 2026: SERD Market Set for Growth During the Forecast Period (2026-2036) as AstraZeneca's ETCAMAH Approval Accelerates Adoption of Oral SERDs | DelveInsight
Oct 2, 2026: Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 14, 2026: Olema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial Results
Sep 14, 2026: Premarket movers: AI stocks slide on warnings, Rumble, Scholar Rock jump
Aug 31, 2026: Olema Oncology to Participate in Upcoming Investor Conferences
Aug 13, 2026: Olema Oncology Appoints Jason O'Byrne as Chief Financial Officer

About Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250.

Similar stocks

Find more stocks like OLMA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.